SAA launches the second “AS Life Impact Study” to poll those affected about onset of symptoms, diagnosis, treatments, medications, and quality of life issues.
The TASC genetic study uncovers three variants in the RUNX3, LTBR-TNFRSF1A, and IL12B regions of the genome as well as additional areas that also seem to play a role – PTGER4, TBKBP1, KIF21B, and CARD9. Other genetic suspects include CDKALI, TRADD and STAT3.